DESIGN OF TISSUE ENGINEERED CONSTRUCT BASED ON DEXTRANOMER AND HYALURONIC ACID FOR THE TREATMENT OF FEMALE STRESS URINARY INCONTINENCE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To design a tissue engineered construct based on stromal cells and a volume-forming agent containing dextranomer and hyaluronic acid as a vehicle for the treatment of female stress urinary incontinence. Subject and methods. Multipotent stromal cells (MSCs) were isolated from human adipose tissue or Wharton’s jelly by enzymatic treatment. For stability evaluation, the volume-forming agent was mixed with growth medium and incubated at 37°C for 7 days and at 4°C for 6 months. The cytotoxicity of the volume-forming agent was evaluated using the MTT test. To combine the components of the tissue engineered construct, MSCs at a concentration of 5 million cells per ml were mixed with an equal volume of the agent and put on a standard culture dish or a dish having low adhesive properties. The construct was let through a 20G needle to estimate cell survival under the conditions simulating transplantation. Results. The cell cultures isolated from human adipose tissue or umbilical cord had a phenotype characteristic of MSCs and responded to inductors of differentiation. The vehicle remained stable for 7 days of incubation at 37°C. Six-month incubation exhibited individual foci of resorption of hyaluronic acid rather than dextran granules. The MTT test showed that the test agent had no cytotoxic activity against human MSCs. Combining the components of the construct on the dish with low adhesive properties was more effective than that on the standard culture dish. Following 2 days, 17.5±8.1 cells were arranged per unit of the vehicle. Longer cultivation gave rise to cell conglomerates. Passing the volume-forming agent suspension, washed from the growth media, with adherent cells through a 20G needle did not cause cell death. Conclusion. The findings confirm that the test volume-forming agent may be used as an injectable microvehicle for tissue engineering.

Full Text

Restricted Access

About the authors

I. V ARUTYUNYAN

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia; Research Institute of Human Morphology, Russian Academy of Medical Sciences

Email: labrosta@yandex.ru
Moscow, Russia

T. Kh FATKHUDINOV

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia; Research Institute of Human Morphology, Russian Academy of Medical Sciences; N.I. Pirogov National Research Medical University

Email: tfat@yandex.ru
Moscow, Russia

A. V MAKAROV

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia; Research Institute of Human Morphology, Russian Academy of Medical Sciences

Email: anvitmak@yandex.ru
Moscow, Russia

T. A TETERINA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: palpebra@inbox.ru
Moscow, Russia

E. Yu KANANYKHINA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia; Research Institute of Human Morphology, Russian Academy of Medical Sciences

Email: e.kananykhina@gmail.com
Moscow, Russia

A. V ELCHANINOV

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia; Research Institute of Human Morphology, Russian Academy of Medical Sciences; N.I. Pirogov National Research Medical University

Email: elchandrey@yandex.ru
Moscow, Russia

A. A KIM

N.I. Pirogov National Research Medical University

Email: calcitonin@mail.ru
Moscow, Russia

O. A VASYUKOVA

N.I. Pirogov National Research Medical University

Email: alison_black@mail.ru
Moscow, Russia

E. E KIRIENKO

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia; Research Institute of Human Morphology, Russian Academy of Medical Sciences

Email: kiriloval@yandex.ru
Moscow, Russia

E. Sh RAIMOVA

N.I. Pirogov National Research Medical University

Email: elram2007@rambler.ru
Moscow, Russia

S. V PAVLOVICH

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: s_pavlovich@oparina4.ru
Moscow, Russia

I. A APOLIKHINA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: apolikhina@inbox.ru
Moscow, Russia

G. T SUKHIKH

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Moscow, Russia

References

  1. Shamliyan T., Wyman J., Bliss D., Kane R., Wilt T. Prevention of urinary and fecal incontinence in adults. Rockville (MD): Agency for Healthcare Research and Quality (US); December, 2007. Report No.: 08-E003.
  2. http://www.clinicaltrials.gov/ct2/results?term=stress+urinar y+incontinence& Search=Search
  3. Stavros C., Ioannis V., Vasileios S.I., Gkotsi A.Ch., Georgios S., Papathanasiou A. et al. Comparison of TVT, TVT-O/TOT and mini slings for the treatment of female stress urinary incontinence: 30 months follow up in 531 patients. Arch. Ital. Urol. Androl. 2012; 84(3): 129—36.
  4. Reynolds W.S., Dmochowski R.R. Urethral bulking: a urology perspective. Urol. Clin. North Am. 2012; 39(3): 279-87. doi: 10.1016/j.ucl.2012.05.002.
  5. Li G.Y., Zhou F., Gong Y.Q., Cui W.S., Yuan Y.M., Song W.D. et al. Activation of VEGF and ERK1/2 and improvement of urethral function by adipose-derived stem cells in a rat stress urinary incontinence model. Urology. 2012; 80(4): 953; e1-8. doi: 10.1016/j.urology.2012.05.030.
  6. Lin C.S., Lue T.F. Stem cell therapy for stress urinary incontinence: a critical review. Stem Cells Dev. 2012; 21(6): 834-43. doi: 10.1089/scd.2011.0621.
  7. Strasser H., Marksteiner R., Margreiter E., Pinggera G.M., Mitterberger M., Frauscher F. et al. Autologous myoblasts and fibroblasts versus collagen for treatment of stress urinary incontinence in women: a randomised controlled trial. Lancet. 2007; 369(9580): 2179—86.
  8. Ho C.P., Bhatia N.N. Development of stem cell therapy for stress urinary incontinence. Curr. Opin. Obstet. Gynecol. 2012; 24(5): 311-7. doi: 10.1097/GCO.0b013e328357ae03.
  9. Макаров А.В., Тетерина Т.А., Саидова А.С., Арутюнян И.В., Фатхудинов Т.Х., Аполихина И.А., Сухих Г.Т. Клеточные технологии в лечении стрессового недержания мочи у женщин. Акушерство и гинекология. 2012; 8(2): 53—9.
  10. Kim B.S., Choi J.S., Kim J.D., Yeo T.Y., Cho Y.W. Improvement of stem cell viability in hyaluronic acid hydrogels using dextran microspheres. J. Biomater. Sci. Polym. Ed. 2010; 21(13): 1701-11. doi: 10.1163/092050609X12548957288848.
  11. Goh T.K., Zhang Z.Y., Chen A.K., Reuveny S., Choolani M., Chan J.K., Oh S.K. Microcarrier culture for efficient expansion and osteogenic differentiation of human fetal mesenchymal stem cells. Biores. Open Access. 2013; 2(2): 84-97. doi: 10.1089/biores.2013.0001.
  12. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4): 315—7.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies